Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Regeneron Pharmaceuticals Inc. buy Barclays PLC

Regeneron Pharmaceuticals Inc.
Start price
€873.50
23.01.24 / 50%
Target price
€938.09
23.01.25
Performance (%)
-24.40%
End price
€660.40
24.01.25
Summary
This prediction ended on 24.01.25 with a price of €660.40. The price of Regeneron Pharmaceuticals Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -24.40%. Barclays_PLC has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Buy. Barclays_PLC has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

AI-generated
Performance without dividends (%)
Name 1w 1m 1y
Regeneron Pharmaceuticals Inc. 1.360% 1.360% 42.407%
iShares Core DAX® -0.874% 5.325% 6.865%
iShares Nasdaq 100 -0.381% 1.979% 25.696%
iShares Nikkei 225® -1.676% 1.952% 41.443%
iShares S&P 500 -0.655% 2.069% 21.405%

Comments by Barclays_PLC for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren
Prediction Buy
Perf. (%) -24.40%
Target price 938.094
Change
Ends at 23.01.25

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Barclays PLC from $935.00 to $1,020.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat

Barclays PLC 
0
Report Share
23.01.24
In the thread Trading Regeneron Pharmaceuticals Inc.
Prediction Buy
Perf. (%) -24.40%
Target price 938.094
Change
Ends at 23.01.25

Die von Barclays_PLC gewählte maximale Laufzeit wurde überschritten

Barclays PLC 
0
Report Share
24.01.25

Current prediction by Barclays_PLC for Regeneron Pharmaceuticals Inc.

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€651.80
06.03.26
€794.33
06.03.27
10.67%
22:25

Barclays PLC 
06.03.26 50%

Stopped prediction by Barclays_PLC for Regeneron Pharmaceuticals Inc.

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€604.40
30.04.26
€785.87
30.04.27
19.35%
22:25

Barclays PLC 
30.04.26 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€775.00
01.11.24
€981.82
01.11.25
-26.71%
02.11.25

Barclays PLC 
01.11.24 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€871.00
23.10.24
€1,001.5
23.10.25
-43.20%
24.10.25

Barclays PLC 
23.10.24 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€990.00
02.08.24
€1,116.5
02.08.25
-51.29%
03.08.25

Barclays PLC 
02.08.24 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€989.60
11.07.24
€1,101.8
11.07.25
-50.80%
12.07.25

Barclays PLC 
11.07.24 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€705.50
07.08.23
€817.83
07.08.24
37.94%
08.08.24

Barclays PLC 
07.08.23 50%